Related Experiment Videos
Poststreptococcal reactive arthritis in children: a retrospective study
Lakshmi Nandini Moorthy1, Sunanda Gaur, Margaret G Peterson
1Department of Pediatrics, Robert Wood Johnson Medical School-UMDNJ, New Brunswick, New Jersey, USA. lnmoorthy@mac.com
Insights
Antibiotic prophylaxis duration for children with poststreptococcal reactive arthritis (PSRA) remains unclear. Long-term cardiac follow-up is recommended, as clinical features and lab values show improvement over time.
Area of Science:
- Pediatrics
- Rheumatology
- Cardiology
Background:
- Poststreptococcal reactive arthritis (PSRA) in children lacks defined treatment durations and prophylaxis guidelines.
- Cardiac involvement is a significant concern in pediatric PSRA.
Purpose of the Study:
- To evaluate clinical features and outcomes in children with PSRA.
- To determine appropriate antibiotic prophylaxis duration and assess cardiac involvement over time.
Main Methods:
- Retrospective chart review of 40 children diagnosed with PSRA.
- Assessment of clinical features and echocardiogram findings at baseline and 6, 12, and 24 months.
- Monitoring of laboratory markers including erythrocyte sedimentation rate and antibody titers.
Main Results:
- 18% of patients had baseline echocardiogram findings; 2 developed findings after 12 months.
- Mean antibiotic prophylaxis duration was 22 months.
- Significant improvement observed in clinical assessments, joint symptoms, and inflammatory markers over 24 months.
Conclusions:
- Children with PSRA demonstrate marked clinical and laboratory improvement over time.
- Long-term cardiac monitoring is advisable for pediatric patients with PSRA.
- Further research is needed to establish definitive antibiotic prophylaxis guidelines.
Abstract:
The duration of treatment and appropriate guidelines for antibiotic prophylaxis for children with poststreptococcal reactive arthritis (PSRA) have not been determined. The authors performed a retrospective chart review of 40 children with PSRA and examined their clinical features at initial evaluation and at 6, 12, and 24 months. At baseline, 18% (n = 7) had a finding noted on the echocardiogram. Although most patients developed cardiac findings early on in the course of their disease, 2 patients with a normal baseline echocardiogram may have developed findings after 12 months of follow-up. The mean duration of prophylaxis was 22 months. During the follow-up period, there was improvement in Physician's Global Assessment, number of patients with arthralgia, tender and swollen joints, erythrocyte sedimentation rate, anti-streptolysin O, and anti-DNAse B antibody titers. The authors conclude that marked improvement in clinical features and laboratory values was seen over time. Patients may benefit with long-term cardiac follow-up.
Related Concept Videos
Streptococcal Pharyngitis
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction
Acute Pyelonephritis II: Diagnostic Studies and Management
Tonsillitis I: Introduction
Etiology
Three primary contributing factors have been identified.